AbbVie’s Skyrizifor received EC approval to treat adults with active psoriatic arthritis
AbbVie announced that the European Commission (EC) has approved Skyrizi (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every... Read More
Case Study: Rinvoq’s brand Dermatology market expansion strategy
Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Rinvoq is the brand of... Read More
AbbVie’s Elezanumab receives US FDA orphan drug and fast track designations
Posted on30 Sep 2020
Comments0
AbbVie announced that the US Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an... Read More
Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment... Read More
Case Analysis: Insight on AbbVie’s acquisition of Allergan
On June 25, 2019, AbbVie Inc. and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie... Read More
Top 10 Global Pharmaceutical Company in 2018
Posted on26 May 2019
Comments0
US FDA grants breakthrough therapy status to AbbVie’s venetoclax in combo with obinutuzumab for untreated adults patients with CLL
AbbVie announced that the US Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in... Read More
USFDA approved Imbruvica in combo with obinutuzumab for adult patients with previously untreated CLL/SLL
AbbVie, a research-based global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the use of Imbruvica (ibrutinib) in... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with... Read More